GlassScriptPhysician profile
Jeffrey W Schultz
NPI 1376622027
$474.12
in general payments reported to CMS, 2019-2025
12 companies · $127 in 2025
The $127 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $27.96 · 2020: $13.63 · 2022: $94.73 · 2023: $166 · 2024: $45.51 · 2025: $127.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $338.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $337.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $96.61 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Bayer Healthcare Pharmaceuticals INC. | $85.27 | 2022-2025 | |
| Lilly USA, LLC | $61.87 | 2022-2025 | Mounjaro, Zepbound |
| Astrazeneca Pharmaceuticals LP | $45.07 | 2023-2025 | Farxiga, Breztri |
| Abbvie INC. | $41.78 | 2022-2023 | Qulipta |
| Amgen INC. | $29.49 | 2022-2023 | Repatha, Otezla |
| Amarin Pharma, INC. | $28.55 | 2019-2020 | |
| Inspire Medical Systems, INC. | $20.84 | 2024 | Inspire |
| Pfizer INC. | $20.75 | 2025 | |
| Tris Pharma INC | $17.00 | 2025 | Dyanavel Xr |
| Exact Sciences Corporation | $14.15 | 2025 | Cologuard Collection Kit |
| Merck Sharp & Dohme LLC | $12.74 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffrey Schultz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.